JHS Svendgaard Laboratories Intrinsic Value
JHS Svendgaard Laboratories (JHS) median intrinsic value is ₹23.00 from 4 valuation models (range ₹11–₹23), vs current price ₹9.20 — +150.0% upside (Trading Below Calculated Value), margin of safety 60.0%. For current market price and key ratios, visit JHS Svendgaard Laboratories share price today.
JHS Valuation Methods Summary — DCF, Graham Number & P/E
JHS Svendgaard Laboratories intrinsic value across 4 models vs current price ₹9.20 — upside/downside and value range per method. Browse JHS quarterly financials for revenue, profit, balance sheet and cash flow data.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| Book Value Method | asset | ₹23.00 | ₹20.70 - ₹25.30 | +150.0% | Book Value/Share: ₹20.12, P/B: 2.5x |
| Revenue Multiple Method | revenue | ₹16.05 | ₹14.45 - ₹17.66 | +74.5% | Revenue/Share: ₹10.70, P/S: 1.5x |
| EBITDA Multiple Method | earnings | ₹11.16 | ₹10.04 - ₹12.28 | +21.3% | EBITDA: ₹8.00Cr, EV/EBITDA: 12x |
| Simple DCF (5Y) | dcf | ₹23.00 | ₹18.40 - ₹27.60 | +150.0% | CF Growth: 15.0%, Discount: 15% |
JHS Intrinsic Value vs Market Price — All Valuation Models
JHS Svendgaard Laboratories fair value range ₹11–₹23 vs current market price ₹9.20 across 4 valuation models. Compare with JHS DCF to assess whether the stock is under or overvalued.
JHS Intrinsic Value Analysis — Undervalued or Overvalued?
JHS Svendgaard Laboratories median intrinsic value ₹23.00, current price ₹9.20 — Trading Below Calculated Value by 150.0%, margin of safety 60.0%.
What is the intrinsic value of JHS?
Based on our comprehensive analysis using 4 different valuation methods, the estimated intrinsic value of JHS Svendgaard Laboratories (JHS) is ₹23.00 (median value). With the current market price of ₹9.20, this represents a +150.0% variance from our estimated fair value.
The valuation range spans from ₹11.16 to ₹23.00, indicating ₹11.16 - ₹23.00.
Is JHS undervalued or overvalued?
Based on our multi-method analysis, JHS Svendgaard Laboratories (JHS) appears to be trading below calculated value by approximately 150.0%.
JHS Financial Health — Key Ratios vs Industry Benchmarks
JHS Svendgaard Laboratories financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 13.50 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Operating Margin | 4.0% | Industry Standard: 20%+ | Below 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.46x | Industry Standard: 1.0x+ | Below 0.5x | Measures asset utilization efficiency |
JHS Cash Flow Quality — Operating & Free Cash Flow
JHS Svendgaard Laboratories operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹-5 Cr | ₹-15 Cr | Negative Cash Flow | 3/10 |
| March 2024 | ₹-9 Cr | ₹-20 Cr | Negative Cash Flow | 3/10 |
| March 2023 | ₹23 Cr | ₹23 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹-9 Cr | ₹-12 Cr | Negative Cash Flow | 3/10 |
| March 2021 | ₹12 Cr | ₹11 Cr | Positive Free Cash Flow | 8/10 |